


Detecting Antimicrobial Resistance A Partnership of PHL and CDC

Roberta B. Carey
Branch Chief, Epidemiology and Laboratory
Division of Healthcare Quality Promotion
CDC

Objectives

1. Understand the clinical and public health importance of resistant microorganisms
2. Learn what organisms are the most important to monitor
3. Recognize the pitfalls in susceptibility testing for detecting resistant bacteria
4. Know the requirements for sending organisms to CDC
5. Understand how PHL and CDC can work together to facilitate rapid reporting of results



Why are we seeing more resistance?

- Overuse of antibiotics for viral illness
- Under-treating infections
 - Stop taking medication before finished
 - Use less potent antibiotics in underdeveloped countries
- Millions of dollars of antibiotics incorporated into livestock feed to bring a better price in the market

How does this affect public health?

- Resistant bacteria transmitted person-to-person perpetuate disease
 - Nosocomial- hospital
 - Community- daycare, nursing homes
- No antibiotics left to use!!
 - Only 8 new agents approved since 1998
- Deadly combination of virulence and resistance
- Resistant organisms in one part of the world only a plane ride away from your world

MRSA

- Methicillin resistant *Staphylococcus aureus* resistant to all penicillinase resistant antibiotics (nafcillin, oxacillin, dicloxacillin)
- Use oxacillin to predict resistance since it is more stable
 - If ox R, then cephalosporin R, amp/sulbactam R
- Population of *S. aureus* is heterogeneous which makes detection of resistance difficult
 - Tests to detect *mecA* gene or its product altered PBP2a more accurate


MRSA





- Common in healthcare setting, now in outpatient population with skin/soft tissue infections, necrotizing pneumonia, septicemia
 - Daycare centers, football and wrestling teams, jails/prisons, msm
 - Unique PFGE type USA300
 - Different *mecA* gene (*mec* type IV)
 - Carries the gene for Panton -Valentine leukocidin (PVL)
 - Clindamycin for therapy requires additional testing to check for inducible resistance (D zone test)
- Nasal colonization facilitates spread of *S. aureus*


VRSA /

- Vancomycin-resistant *S. aureus* and vancomycin-intermediate *S. aureus*
- Public health issue since vancomycin is routinely used to treat MRSA
- 3 strains of VRSA: MI, PA, NY
 - *S. aureus* acquired the *vanA* gene from enterococci
 - Surveillance revealed no transmission
- All potential VRSA and VISA (vanc > 4 µg/ml, growth on vancomycin screening agar) should be sent to CDC for confirmation ASAP










VRE


- Vancomycin-resistant enterococci (*E. faecium* and *E. faecalis*)
- Dangerous mix of already resistant bugs now resistant to the most widely prescribed antibiotic used to treat Gram positive infections
- Enterococci important cause of nosocomial bacteremia, surgical site infection and UTI
- Spread in healthcare environment on hands of personnel or contact with contaminated objects
- Treatment with new antibiotics (linezolid, quinopristin/dalfopristin)


Biochemical Tests to ID Enterococci



Additional Tests to Detect Species with Intrinsic Vancomycin Resistance







MDRSP

- Multidrug resistant *Streptococcus pneumoniae*
 - Resistant to pen, SXT, erythromycin, tetracycline, third generation cephalosporins
 - Resistant organisms easily spread in daycare settings
- New polysaccharide conjugate vaccine with 7 most common serotypes of pneumococci seen in children protects vaccinated and those around them (herd effect)

ESBL

- Extended spectrum beta lactamases destroy activity of all penicillins, cephalosporins, aztreonam
- Clinical importance
 - High failure rates with ESBLs treated with cephalosporins
 - ESBL producing organisms significant infection control problems
 - *E. coli*, *Klebsiella* spp., *Proteus mirabilis*, *Salmonella*
 - Carbapenems (imipenem) drug of choice

ESBL


- Screen for resistance based on MIC ≥ 2 $\mu\text{g/ml}$ or disk diffusion zone sizes
- Must perform confirmatory tests using clavulanic acid to reverse activity ≥ 3 fold decrease in MIC or 5mm increase
- If positive, change S/I to R for all cephalosporins

ceftazidime



14 mm

ceftaz/clav



20 mm

AmpC Beta lactamases


- Chromosomal mediated in *Enterobacter*, *Serratia*, *Citrobacter*, *Morganella*, *Providencia*
- Plasmid-mediated in *E. coli* and *Klebsiella*
- Enzymes are resistant to the effects of beta-lactamase inhibitors
- Enzymes hydrolyze cephalosporins and cephamycins (cefoxitin and cefotetan)
- No standardized method of detection in the lab

MDR GNR

- *Acinetobacter baumannii* resistant to all routinely used antibiotics
- *Klebsiella* resistant to imipenem and cephalosporins
- Resistance to > 3 classes of antibiotics in *Ps. aeruginosa* increased from 4% in 1993 to 14% in 2002
- Inappropriate empiric treatment group had 38.4% mortality rate compared 27.4% for patients given at least one active antibiotic

How do clinical labs detect resistance?

- Large labs with high volume testing use automated instruments for ID/susceptibility
 - Rapid results, labor saving
 - May sacrifice accuracy, limited flexibility of antibiotics tested
- Disk diffusion
 - Technically simple
 - More cumbersome, slower to get a result
- E test
 - Combines MIC and diffusion method
 - Labor intensive and costly



Pitfalls in Current Susceptibility Testing

- Automation may overcall MRSA
- Automation may not detect VRSA
- Automation does not detect inducible resistance in clindamycin
- Disk diffusion may not detect VRE and VISA
- ESBL detection requires confirmatory testing
- Interpretation of pneumococcal antibiotics depends on meningitis or non-meningitis

How can PHL help?

- First line resource to the smaller clinical labs
- Disseminate accurate advice
- Perform reference testing to confirm unusual results
- Gather data to track area-wide resistance
- Compile state-wide antibiogram

How can PHL be a good partner with CDC?

- Provide required information about the isolate
 - Patient demographics
 - Specimen source
 - Growth requirements of the organism (temperature, atmosphere, media)
 - Biochemical reactions of your testing
 - Give your "best guess" so it goes to the right lab
- Your name and phone number at PHL

Information must be completed by State health department laboratory before specimen can be accepted by CDC. Please check the CDC application statement if and when appropriate complete the statement with the following information:

Choose specimen to be of public health importance. Specimen to:

(a) from an outbreak, (b) from uncommon or exotic disease, (c) an isolate that cannot be identified, is atypical, shows multiple antibiotic resistance, or from a normally sterile site, (d) from a disease for which reliable diagnostic reagents or expertise are unavailable in State.

Copying cost under the CDC State project.
 Contribution of results requested for quality assurance.

Price arrangement for testing has been made.

Please provide the following information:

Microbiologist name and phone

(Name): _____

Native, Address and Phone Number of Physician or Organization: _____

Get phone # of submitting lab/doctor

STATE HEALTH DEPARTMENT LABORATORY ADDRESS: _____

Completed by: _____

STATE HEALTH DEPARTMENT: _____ DATE SENT TO CDC: _____ (MM/DD/YYYY)

PATIENT IDENTIFICATION: (Hospital No.) _____

NAME (LAST, FIRST, MI): _____

BIRTHDATE: (MM/DD/YYYY) _____ SEX: MALE FEMALE

(FOR CDC USE ONLY)		CDC NUMBER	DATE RECEIVED	ASSOCIATED ILLNESS		
UNIT	PT NUMBER	NUMBER	MO	DA	YES	NO

DATE OF ONSET: (MM/DD/YYYY) _____ FATAL? YES NO
